machineMD has successfully completed the first round of the DayOne 4.0 Health Accelerator and has been selected for the next round. The team was selected from over 100 applicants across 35 countries and qualified into the top 5 startups who progressed from the 15 startups in the initial phase of the program. An important achievement that will have a positive impact on machineMD and its first product, neos™, a non-invasive device for an automatic, quantitative, standardized neuro-ophthalmological examination.
DayOne is an initiative of Basel Are Business & Innovation. The aim is to promote partnerships between established life science companies and promising new innovations in the healthcare sector. The DayOne team consists of volunteer industry experts, medical doctors, tech enthusiasts and researchers.
The first phase of the DayOne Health 4.0 Accelerator took place from September to November 2023. machineMD was one of four Swiss startups, and is the only one to make it through to the final round. The team will receive support for another three months, including 1:1 mentoring, expert input and introductions to relevant healthcare stakeholders.
Phil Norris, Chief Commercial Officer and participant in the program, is excited about this achievement: “Our success in this program demonstrates the importance of our mission to radically improve the measurement of brain function. With the insightful support of the DayOne Health 4.0 Accelerator experts, machineMD is equipped to scale its success with global industry leaders.”
In addition to machineMD, the following start-ups have reached the final phase: Briya from Israel, CliniNote from Poland, FindMeCure/TrialHub based in Bulgaria and Italian startup InSilicoTrials Technologies.